Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade

Cancer Cell

Volumn 32, Issue 2, 2017, Pages 253-267.e5

  Saha, Dipongkor ^a,b   Martuza, Robert L ^a,b   Rabkin, Samuel D ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

cancer stem cells; glioma; HSV; immunotherapy; oncolytic virus

Indexed keywords

CHECKPOINT KINASE INHIBITOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; G47 DELTA; IMMUNOGLOBULIN G; INTERLEUKIN 12; ONCOLYTIC HERPES VIRUS; PROGRAMMED DEATH 1 ANTIBODY; PROGRAMMED DEATH LIGAND 1 ANTIBODY; UNCLASSIFIED DRUG; CD274 PROTEIN, HUMAN; CTLA4 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY; ONCOLYTIC VIRUS; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ERADICATION; DRUG EFFICACY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MACROPHAGE; MOUSE; NONHUMAN; ONCOLOGICAL PARAMETERS; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL CYCLE CHECKPOINT; DISEASE MODEL; DRUG EFFECTS; FEMALE; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; MACROPHAGE ACTIVATION; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY; TUMOR CELL CULTURE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL CYCLE CHECKPOINTS; COMBINED MODALITY THERAPY; CTLA-4 ANTIGEN; DISEASE MODELS, ANIMAL; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-12; MACROPHAGE ACTIVATION; MACROPHAGES; MICE; MICE, INBRED C57BL; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PROGRAMMED CELL DEATH 1 RECEPTOR; TUMOR CELLS, CULTURED;

EID: 85026835210     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2017.07.006     Document Type: Article

References (69)

1. Agarwalla, P., Barnard, Z., Fecci, P., Dranoff, G., Curry, W.T. Jr., Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors. J. Immunother. 35 (2012), 385–389.
2. Antonia, S.J., Lopez-Martin, J.A., Bendell, J., Ott, P.A., Taylor, M., Eder, J.P., Jager, D., Pietanza, M.C., Le, D.T., de Braud, F., et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 17 (2016), 883–895.
3. Badie, B., Schartner, J.M., Flow cytometric characterization of tumor-associated macrophages in experimental gliomas. Neurosurgery 46 (2000), 957–961 discussion 961–952.
4. Binello, E., Qadeer, Z.A., Kothari, H.P., Emdad, L., Germano, I.M., Stemness of the CT-2A immunocompetent mouse brain tumor model: characterization in vitro. J. Cancer 3 (2012), 166–174.
5. Butowski, N., Colman, H., De Groot, J.F., Omuro, A.M., Nayak, L., Wen, P.Y., Cloughesy, T.F., Marimuthu, A., Haidar, S., Perry, A., et al. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro Oncol. 18 (2016), 557–564.
6. Carlsson, S.K., Brothers, S.P., Wahlestedt, C., Emerging treatment strategies for glioblastoma multiforme. EMBO Mol. Med. 6 (2014), 1359–1370.
7. Cheema, T.A., Wakimoto, H., Fecci, P.E., Ning, J., Kuroda, T., Jeyaretna, D.S., Martuza, R.L., Rabkin, S.D., Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model. Proc. Natl. Acad. Sci. USA 110 (2013), 12006–12011.
8. Cockle, J.V., Rajani, K., Zaidi, S., Kottke, T., Thompson, J., Diaz, R.M., Shim, K., Peterson, T., Parney, I.F., Short, S., et al. Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling. Neuro Oncol. 18 (2016), 518–527.
9. + T cells. Immunity 22 (2005), 371–383.
10. Curran, M.A., Montalvo, W., Yagita, H., Allison, J.P., PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl. Acad. Sci. USA 107 (2010), 4275–4280.
11. Curry, W.T., Lim, M., Immunomodulation: checkpoint blockade etc. Neuro Oncol. 17:Suppl 7 (2015), vii26–vii31.
12. Di Tomaso, T., Mazzoleni, S., Wang, E., Sovena, G., Clavenna, D., Franzin, A., Mortini, P., Ferrone, S., Doglioni, C., Marincola, F.M., et al. Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin. Cancer Res. 16 (2010), 800–813.
13. Fecci, P.E., Ochiai, H., Mitchell, D.A., Grossi, P.M., Sweeney, A.E., Archer, G.E., Cummings, T., Allison, J.P., Bigner, D.D., Sampson, J.H., Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin. Cancer Res. 13 (2007), 2158–2167.
14. Haabeth, O.A., Tveita, A.A., Fauskanger, M., Schjesvold, F., Lorvik, K.B., Hofgaard, P.O., Omholt, H., Munthe, L.A., Dembic, Z., Corthay, A., Bogen, B., How do CD4(+) T cells detect and eliminate tumor cells that either lack or express MHC class II molecules?. Front Immunol., 5, 2014, 174.
15. Kennedy, B.C., Showers, C.R., Anderson, D.E., Anderson, L., Canoll, P., Bruce, J.N., Anderson, R.C., Tumor-associated macrophages in glioma: friend or foe?. J. Oncol., 2013, 2013, 486912.
16. Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.J., Cowey, C.L., Lao, C.D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373 (2015), 23–34.
17. Lathia, J.D., Mack, S.C., Mulkearns-Hubert, E.E., Valentim, C.L., Rich, J.N., Cancer stem cells in glioblastoma. Genes Dev. 29 (2015), 1203–1217.
18. Le, D.T., Ladle, B.H., Lee, T., Weiss, V., Yao, X., Leubner, A., Armstrong, T.D., Jaffee, E.M., CD8(+) Foxp3(+) tumor infiltrating lymphocytes accumulate in the context of an effective anti-tumor response. Int. J. Cancer 129 (2011), 636–647.
19. Liu, Z., Ravindranathan, R., Kalinski, P., Guo, Z.S., Bartlett, D.L., Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. Nat. Commun., 8, 2017, 14754.
20. Lussier, D.M., Johnson, J.L., Hingorani, P., Blattman, J.N., Combination immunotherapy with alpha-CTLA-4 and alpha-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma. J. Immunother. Cancer, 3, 2015, 21.
21. Maes, W., Van Gool, S.W., Experimental immunotherapy for malignant glioma: lessons from two decades of research in the GL261 model. Cancer Immunol. Immunother. 60 (2011), 153–160.
22. Mandai, M., Hamanishi, J., Abiko, K., Matsumura, N., Baba, T., Konishi, I., Dual faces of IFNgamma in cancer progression: a role of PD-L1 Induction in the determination of pro- and antitumor immunity. Clin. Cancer Res. 22 (2016), 2329–2334.
23. Mantovani, A., Allavena, P., The interaction of anticancer therapies with tumor-associated macrophages. J. Exp. Med. 212 (2015), 435–445.
24. Martin-Orozco, N., Muranski, P., Chung, Y., Yang, X.O., Yamazaki, T., Lu, S., Hwu, P., Restifo, N.P., Overwijk, W.W., Dong, C., T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 31 (2009), 787–798.
25. Marumoto, T., Tashiro, A., Friedmann-Morvinski, D., Scadeng, M., Soda, Y., Gage, F.H., Verma, I.M., Development of a novel mouse glioma model using lentiviral vectors. Nat. Med. 15 (2009), 110–116.
26. Mellman, I., Hubbard-Lucey, V.M., Tontonoz, M.J., Kalos, M.D., Chen, D.S., Allison, J.P., Drake, C.G., Levitsky, H., Lonberg, N., van der Burg, S.H., et al. De-risking immunotherapy: report of a consensus workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute. Cancer Immunol. Res. 4 (2016), 279–288.
27. Murray, P.J., Allen, J.E., Biswas, S.K., Fisher, E.A., Gilroy, D.W., Goerdt, S., Gordon, S., Hamilton, J.A., Ivashkiv, L.B., Lawrence, T., et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 41 (2014), 14–20.
28. Nghiem, P.T., Bhatia, S., Lipson, E.J., Kudchadkar, R.R., Miller, N.J., Annamalai, L., Berry, S., Chartash, E.K., Daud, A., Fling, S.P., et al. PD-1 blockade with pembrolizumab in advanced merkel-cell carcinoma. N. Engl. J. Med. 374 (2016), 2542–2552.
29. Nigim, F., Cavanaugh, J., Patel, A.P., Curry, W.T. Jr., Esaki, S., Kasper, E.M., Chi, A.S., Louis, D.N., Martuza, R.L., Rabkin, S.D., Wakimoto, H., Targeting hypoxia-inducible factor 1alpha in a new orthotopic model of glioblastoma recapitulating the hypoxic tumor microenvironment. J. Neuropathol. Exp. Neurol. 74 (2015), 710–722.
30. Noy, R., Pollard, J.W., Tumor-associated macrophages: from mechanisms to therapy. Immunity 41 (2014), 49–61.
31. Oh, T., Fakurnejad, S., Sayegh, E.T., Clark, A.J., Ivan, M.E., Sun, M.Z., Safaee, M., Bloch, O., James, C.D., Parsa, A.T., Immunocompetent murine models for the study of glioblastoma immunotherapy. J. Transl. Med., 12, 2014, 107.
32. Ott, P.A., Hodi, F.S., Talimogene laherparepvec for the treatment of advanced melanoma. Clin. Cancer Res. 22 (2016), 3127–3131.
33. Peng, L.S., Zhuang, Y., Shi, Y., Zhao, Y.L., Wang, T.T., Chen, N., Cheng, P., Liu, T., Liu, X.F., Zhang, J.Y., et al. Increased tumor-infiltrating CD8(+)Foxp3(+) T lymphocytes are associated with tumor progression in human gastric cancer. Cancer Immunol. Immunother. 61 (2012), 2183–2192.
34. Perez-Diez, A., Joncker, N.T., Choi, K., Chan, W.F., Anderson, C.C., Lantz, O., Matzinger, P., CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 109 (2007), 5346–5354.
35. Perng, P., Lim, M., Immunosuppressive mechanisms of malignant gliomas: parallels at non-CNS sites. Front Oncol., 5, 2015, 153.
36. Peters, C., Rabkin, S.D., Designing herpes viruses as oncolytics. Mol. Ther. Oncolytics, 2, 2015, 10.1038/mto.2015.10.
37. Preusser, M., Berghoff, A.S., Wick, W., Weller, M., Clinical neuropathology mini-review 6-2015: PD-L1: emerging biomarker in glioblastoma?. Clin. Neuropathol. 34 (2015), 313–321.
38. Preusser, M., Lim, M., Hafler, D.A., Reardon, D.A., Sampson, J.H., Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nat. Rev. Neurol. 11 (2015), 504–514.
39. Puzanov, I., Milhem, M.M., Minor, D., Hamid, O., Li, A., Chen, L., Chastain, M., Gorski, K.S., Anderson, A., Chou, J., et al. Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma. J. Clin. Oncol. 34 (2016), 2619–2626.
40. Pyonteck, S.M., Akkari, L., Schuhmacher, A.J., Bowman, R.L., Sevenich, L., Quail, D.F., Olson, O.C., Quick, M.L., Huse, J.T., Teijeiro, V., et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. 19 (2013), 1264–1272.
41. Quezada, S.A., Peggs, K.S., Simpson, T.R., Allison, J.P., Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunol. Rev. 241 (2011), 104–118.
42. Rajani, K., Parrish, C., Kottke, T., Thompson, J., Zaidi, S., Ilett, L., Shim, K.G., Diaz, R.M., Pandha, H., Harrington, K., et al. Combination therapy with reovirus and anti-PD-1 blockade controls tumor growth through innate and adaptive immune responses. Mol. Ther. 24 (2016), 166–174.
43. Reardon, D.A., Gokhale, P.C., Klein, S.R., Ligon, K.L., Rodig, S.J., Ramkissoon, S.H., Jones, K.L., Conway, A.S., Liao, X., Zhou, J., et al. Glioblastoma eradication following immune checkpoint blockade in an orthotopic, immunocompetent model. Cancer Immunol. Res. 4 (2016), 124–135.
44. Robert, C., Schachter, J., Long, G.V., Arance, A., Grob, J.J., Mortier, L., Daud, A., Carlino, M.S., McNeil, C., Lotem, M., et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372 (2015), 2521–2532.
45. Rojas, J.J., Sampath, P., Hou, W., Thorne, S.H., Defining effective combinations of immune checkpoint blockade and oncolytic virotherapy. Clin. Cancer Res. 21 (2015), 5543–5551.
46. Rolny, C., Mazzone, M., Tugues, S., Laoui, D., Johansson, I., Coulon, C., Squadrito, M.L., Segura, I., Li, X., Knevels, E., et al. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 19 (2011), 31–44.
47. Saha, D., Ahmed, S.S., Rabkin, S.D., Exploring the antitumor effect of virus in malignant glioma. Drugs Future 40 (2015), 739–749.
48. Sayour, E.J., McLendon, P., McLendon, R., De Leon, G., Reynolds, R., Kresak, J., Sampson, J.H., Mitchell, D.A., Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma. Cancer Immunol. Immunother. 64 (2015), 419–427.
49. Seyfried, T.N., el-Abbadi, M., Ecsedy, J.A., Bai, H.W., Yohe, H.C., Influence of host cell infiltration on the glycolipid content of mouse brain tumors. J. Neurochem. 66 (1996), 2026–2033.
50. Sharma, P., Allison, J.P., Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161 (2015), 205–214.
51. Shen, W., Patnaik, M.M., Ruiz, A., Russell, S.J., Peng, K.W., Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia. Blood 127 (2016), 1449–1458.
52. Simpson, T.R., Li, F., Montalvo-Ortiz, W., Sepulveda, M.A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J.Y., Yagita, H., Wolchok, J.D., et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med. 210 (2013), 1695–1710.
53. Soda, Y., Marumoto, T., Friedmann-Morvinski, D., Soda, M., Liu, F., Michiue, H., Pastorino, S., Yang, M., Hoffman, R.M., Kesari, S., Verma, I.M., Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc. Natl. Acad. Sci. USA 108 (2011), 4274–4280.
54. Todo, T., Martuza, R.L., Rabkin, S.D., Johnson, P.A., Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc. Natl. Acad. Sci. USA 98 (2001), 6396–6401.
55. Topalian, S.L., Drake, C.G., Pardoll, D.M., Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27 (2015), 450–461.
56. Topalian, S.L., Taube, J.M., Anders, R.A., Pardoll, D.M., Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat. Rev. Cancer 16 (2016), 275–287.
57. Tugues, S., Burkhard, S.H., Ohs, I., Vrohlings, M., Nussbaum, K., Vom Berg, J., Kulig, P., Becher, B., New insights into IL-12-mediated tumor suppression. Cell Death Differ. 22 (2015), 237–246.
58. Twyman-Saint Victor, C., Rech, A.J., Maity, A., Rengan, R., Pauken, K.E., Stelekati, E., Benci, J.L., Xu, B., Dada, H., Odorizzi, P.M., et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520 (2015), 373–377.
59. Ugel, S., De Sanctis, F., Mandruzzato, S., Bronte, V., Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. J. Clin. Invest. 125 (2015), 3365–3376.
60. Vom Berg, J., Vrohlings, M., Haller, S., Haimovici, A., Kulig, P., Sledzinska, A., Weller, M., Becher, B., Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell-mediated glioma rejection. J. Exp. Med. 210 (2013), 2803–2811.
61. Wainwright, D.A., Chang, A.L., Dey, M., Balyasnikova, I.V., Kim, C.K., Tobias, A., Cheng, Y., Kim, J.W., Qiao, J., Zhang, L., et al. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin. Cancer Res. 20 (2014), 5290–5301.
62. Wakimoto, H., Kesari, S., Farrell, C.J., Curry, W.T. Jr., Zaupa, C., Aghi, M., Kuroda, T., Stemmer-Rachamimov, A., Shah, K., Liu, T.C., et al. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res. 69 (2009), 3472–3481.
63. Wakimoto, H., Mohapatra, G., Kanai, R., Curry, W.T. Jr., Yip, S., Nitta, M., Patel, A.P., Barnard, Z.R., Stemmer-Rachamimov, A.O., Louis, D.N., et al. Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells. Neuro Oncol. 14 (2012), 132–144.
64. Woller, N., Gurlevik, E., Fleischmann-Mundt, B., Schumacher, A., Knocke, S., Kloos, A.M., Saborowski, M., Geffers, R., Manns, M.P., Wirth, T.C., et al. Viral infection of tumors overcomes resistance to PD-1-immunotherapy by broadening neoantigenome-directed T-cell responses. Mol. Ther. 23 (2015), 1630–1640.
65. Wu, A., Wei, J., Kong, L.Y., Wang, Y., Priebe, W., Qiao, W., Sawaya, R., Heimberger, A.B., Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol. 12 (2010), 1113–1125.
66. Yuan, A., Hsiao, Y.J., Chen, H.Y., Chen, H.W., Ho, C.C., Chen, Y.Y., Liu, Y.C., Hong, T.H., Yu, S.L., Chen, J.J., Yang, P.C., Opposite effects of M1 and M2 macrophage subtypes on lung cancer progression. Sci. Rep., 5, 2015, 14273.
67. Zamarin, D., Holmgaard, R.B., Subudhi, S.K., Park, J.S., Mansour, M., Palese, P., Merghoub, T., Wolchok, J.D., Allison, J.P., Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci. Transl. Med., 6, 2014, 226ra232.
68. Zeng, J., See, A.P., Phallen, J., Jackson, C.M., Belcaid, Z., Ruzevick, J., Durham, N., Meyer, C., Harris, T.J., Albesiano, E., et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int. J. Radiat. Oncol. Biol. Phys. 86 (2013), 343–349.
69. Zhou, W., Ke, S.Q., Huang, Z., Flavahan, W., Fang, X., Paul, J., Wu, L., Sloan, A.E., McLendon, R.E., Li, X., et al. Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth. Nat. Cell Biol. 17 (2015), 170–182.